Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 249-528-5 | CAS number: 29232-93-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Exposure related observations in humans: other data
Administrative data
- Endpoint:
- exposure-related observations in humans: other data
- Type of information:
- experimental study
- Adequacy of study:
- supporting study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- study well documented, meets generally accepted scientific principles, acceptable for assessment
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 976
- Report date:
- 1976
Materials and methods
- Type of study / information:
- 56-day oral repeated dose toxicity study
- Endpoint addressed:
- repeated dose toxicity: oral
- Principles of method if other than guideline:
- A group of seven healthy human volunteers, consisting of three males and four females, was given orally a dose of 0.25 mg test substance/kg bw/day in capsule form for a period of 56 days. Two healthy female volunteers took a blank capsule over the same period. The effect of the administration on liver function, blood count and erythrocyte and plasma cholinesterase activity was evaluated.
- GLP compliance:
- no
Test material
- Reference substance name:
- Pirimiphos-methyl
- EC Number:
- 249-528-5
- EC Name:
- Pirimiphos-methyl
- Cas Number:
- 29232-93-7
- Molecular formula:
- C11H20N3O3PS
- IUPAC Name:
- O-2-(diethylamino)-6-methylpyrimidin-4-yl O,O-dimethyl phosphorothioate
Constituent 1
Method
- Ethical approval:
- not specified
- Details on study design:
- Initially, eight healthy males and eight healthy females volunteered for the study. These were divided into two equal groups of four males and four females, one to be given capsules containing the substance and the other group to be given blank capsules, as a control. At the beginning of the trial, however, a number withdrew for various reasons, leaving only three males and six females. It was decided that two of the females should continue to act as controls. The nature of the trial was explained fully to each volunteer and each signed a form of consent. None had any known contact with organophosphates or carbamates before the trial, nor, apart from the given in dosing, during the trial. All were medically examined before the trial and care was taken to ensure that none had a history or past or present liver disease, alcoholism or were on potentially hepatotoxic drug regimes. The males were 22 to 27 years of age and weighed 62 to 82 kg, the females were 21 to 49 years of age and weighed 44 to 63 kg. The two control females were 20 and 30 years of age and weighed 44 and 46 kg.
Blood was taken twice by venepuncture at the antecubital fossa from each volunteer in the week before dosing began to determine plasma and erythrocyte cholinesterase activities which, together with the sample taken on day 1 of dosing schedule, provided mean pre-experimental baseline values. Plasma alanine amino-transferase, aspartate aminotransferase, alkaline phosphatase, gamma-glutamyl transpeptidase activities and full blood counts were determined on the second pre-dosing sample.
The test substance was given to the seven subjects at a dose of 0.25 mg/kg bw/day for a period of 56 days. The two controls were given a blank capsule each day for the same period. The capsules were taken at mid-morning each day and the blood samples were taken between 8.45 and 9.15 hours on days 7, 14, 21, 28, 35, 42, 49 and 56 after dosing began and also in the recovery period at days 7, 14, 21 and 28 after dosing had stopped, for the determination of plasma and erythrocyte cholinesterase activities. Liver function tests and full blood counts were carried out on day 56 of dosing and on day 28 of the recovery period. - Exposure assessment:
- estimated
- Details on exposure:
- The doses were prepared by injecting the required amount of test substance into gelatin capsules by means of a graduated 100 µL Hamilton syringe. The capsules were heat sealed. The test substance was shown to be stable in contact with gelatin over a period of seven days by gas chromatographic analysis of the capsule content. The capsules for the controls were prepared by heat sealing the blank gelatin capsules using a pasteur pipette. All procedures were carried out under aseptic conditions in a fume cupboard.
Results and discussion
- Results:
- Blood counts and erythrocyte cholinesterase activity showed little change throughout the period of the trial. Slight changes in the levels of activity of gamma-glutamyl transpeptidase in the volunteers were also seen in the control subjects and values remained within normal limits. Such fluctuations probably represent the normal pattern of variation. Other plasma enzymes showed similar but less marked variations and again all results were within normal limits. Although other studies have shown apparent effects on the liver by long term low dose exposure to organophosphorus compounds (Grech 1965, Tocci et al. 1969), this was not demonstrated in the present investigation.
Plasma cholinesterase activity showed a greater degree of variation than other parameters. Examination of the data suggests a tendency for levels of activity in those receiving the test substance to fall slightly over the first 28 days of dosing, but this was not progressive and the values tended to rise slightly after day 28 and this was also seen in the recovery period. Individual values except for two subjects (F2 and F4) showed coefficients of variation between 5 and 10% which accords well with the controls (10.4 and 9.8%) and also observations on normal populations with a figure of 7.6% for the mean individual coefficient of variation for plasma cholinesterase.
Two of the females exposed to the substance (F2 and F4) showed decreases in plasma cholinesterase activity. At day 28 of treatment, the value for subject F2 had fallen to 77.5% of the pre-experimental mean and for subject F4 had fallen to 74.1%. Their respective coefficients of variation were 13.3 and 12.2%. At the end of the dosing period, plasma cholinesterase activity had risen to 83% and 87% of the pre-experimental values. The reductions in the plasma cholinesterase activity may represent a minimal response to the test substance, but there was no evidence of a progressive fall in activity over the period of dosing which may be the result of a compensatory increase in the rate of enzyme synthesis. Overall, the degree of depression was considered to be of dubious biological significance.
The overall results of the study confirmed the previous results indicating that repeated oral exposure to the substance at a dose of 0.25 mg/kg bw/day produced no adverse effects on the liver function, the plasma and erythrocyte cholinesterase activity, or the peripheral blood picture.
Applicant's summary and conclusion
- Conclusions:
- The overall results of the study confirmed that repeated oral exposure to the substance at a dose of 0.25 mg/kg bw/day over a period of 56 consecutive days produced no adverse effects on the liver function, the plasma and erythrocyte cholinesterase activity, or the peripheral blood picture in humans.
- Executive summary:
In this study, the test substance was administered orally for a period of 56 days at a dose of 0.25 mg/kg bw/day to seven human volunteers, three males and four females. The doses were prepared by injecting the required amount of test substance into gelatin capsules by means of a graduated 100 µL Hamilton syringe. The capsules were heat sealed. The test substance was shown to be stable in contact with gelatin over a period of seven days by gas chromatographic analysis of the capsule content. Two further females were given blank gelatin capsules without test substance over the same period. In the week prior to dosing, two samples of blood were submitted by all human volunteers for pre-experimental cholinesterase activity assay. The volunteers then took a daily oral dose of 0.25 mg/kg bw/day for 56 days, or were given the blank gelatin capsule for the same period. The dose was taken orally by capsule at mid-morning each day. Blood samples were taken between 8.45 and 9.15 hours on days 7, 14, 21, 28, 35, 42, 49 and 56 after the commencement of administration. Blood samples were submitted 7, 14, 21 and 28 days after cessation of dosing. All samples were used to analyse the plasma and erythrocyte cholinesterase activities. Liver function tests and full blood counts were carried out on day 56 of dosing and on day 28 of the recovery period.
Two of the females exposed to the test substance showed decreases in plasma cholinesterase activity. At day 28 of treatment, the value had fallen to 77.5% and 74.1% of the pre-experimental mean. Their respective coefficients of variation were 13.3 and 12.2%. At the end of the dosing period, plasma cholinesterase activity had risen to 83% and 87% of the pre-experimental values. The reductions in the plasma cholinesterase activity may represent a minimal response to the test substance, but there was no evidence of a progressive fall in activity over the period of dosing which may be the result of a compensatory increase in the rate of enzyme synthesis. Overall, the degree of depression was considered to be of dubious biological significance and within the generally observed variation in normal subjects.
The overall results of the study confirmed the previous results indicating that repeated oral exposure to the substance at a dose of 0.25 mg/kg bw/day produced no adverse effects on the liver function, the plasma and erythrocyte cholinesterase activity, or the peripheral blood picture.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.